A longitudinal, prospective, observational, multicentre study of patients with rheumatoid arthritis treated with certolizumab pegol

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 Sep 2020 Results describing long-term effectiveness and safety of certolizumab pegol in patients with moderate-to-severe rheumatoid arthritis published in the Clinical and Experimental Rheumatology
14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
24 Oct 2018 Final 36-month follow up results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com